Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.

Journal of experimental & clinical cancer research : CR - 1 Feb 2017

Bista Ranjan, Lee David W, Pepper Oliver B, Azorsa David O, Arceci Robert J, Aleem Eiman

Abstract excerpt

BACKGROUND: Children with Down syndrome (DS) have increased risk for developing AML (DS-AMKL), and they usually experience severe therapy-related toxicities compared to non DS-AMKL. Refractory/relapsed disease has very poor outcome, and patients would benefit from novel, less toxic, therapeutic strategies that overcome resistance. Relapse/resistance are linked to cancer stem cells with high aldehyde dehydrogenase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Dehydrogenase
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Cytarabine

Share to Down Syndrome

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myeloid, Acute

Share to Proteasome Endopeptidase Complex

Source

Open in PubMed Open full text

Identifiers

PMID: 28143565
DOI: 10.1186/s13046-017-0493-5
PMCID: PMC5286849

Genes

PSMB5

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.PMID 28143565Read ↗

Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalitiesSemantic proximity Read ↗

Resistance to targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLSemantic proximity Read ↗

Metabolic vulnerabilities in Down syndrome B-cell acute lymphoblastic leukemia can be targeted using VenetoclaxSemantic proximity Read ↗

The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell LinesSemantic proximity Read ↗

Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemiaSemantic proximity Read ↗

Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolismSemantic proximity Read ↗

Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex<i>in vitro</i>and<i>in vivo</i>in patient-derived xenograft modelsSemantic proximity Read ↗

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cellsSemantic proximity Read ↗

Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.Semantic proximity Read ↗

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cellsSemantic proximity Read ↗

Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.